A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...

Dupilumab yields larger improvements in lung function than several other biologics in patients with severe asthma.

For children with atopic dermatitis (AD), dupilumab treatment restores skin barrier function, according to a study published online Jan. 26 in the Annals of All ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

MONTREAL — Ocular surface disease (OSD) in patients with atopic dermatitis (AD) treated with dupilumab may be exacerbated rather than caused by the therapy, according to a study presented at the ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

Researchers found that dupilumab improved skin barrier integrity and reduced inflammation in children with atopic dermatitis.